ivosidenib + futibatinib + zanidatamab + neratinib + trastuzumab + encorafenib + binimetinib

This is a combination regimen of seven targeted anti-cancer agents: **ivosidenib** (an isocitrate dehydrogenase 1 inhibitor), **futibatinib** (a fibroblast growth factor receptor inhibitor), **zanidatamab** (a bispecific monoclonal antibody targeting two epitopes on HER2), **neratinib** (an irreversible pan-HER tyrosine kinase inhibitor), **trastuzumab** (a monoclonal antibody against HER2), **encorafenib** (a BRAF inhibitor), and **binimetinib** (a MEK inhibitor). Each drug targets different but often interconnected cancer pathways, commonly used in precision oncology trials or compassionate use for cancers with highly complex molecular profiles, usually after standard therapy failure. Several of these agents (zanidatamab, neratinib, trastuzumab) specifically target HER2, either through direct binding or kinase inhibition, suggesting this combination is intended for malignancies with HER2 amplification/mutation in addition to other actionable mutations.

Brand names

Herceptin (trastuzumab)NERLYNX (neratinib)Ziihera (zanidatamab-hrii)Braftovi (encorafenib)Mektovi (binimetinib)